Fortrea (NASDAQ:FTRE – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Risk and Volatility
Fortrea has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.71, suggesting that its share price is 371% less volatile than the S&P 500.
Earnings & Valuation
This table compares Fortrea and Bullfrog AI”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fortrea | $2.68 billion | 0.71 | -$986.20 million | ($0.91) | -21.86 |
| Bullfrog AI | $120,000.00 | 102.84 | -$6.50 million | ($0.46) | -1.45 |
Bullfrog AI has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Fortrea and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortrea | -3.18% | 10.72% | 2.17% |
| Bullfrog AI | N/A | -150.36% | -127.98% |
Insider & Institutional Ownership
1.0% of Bullfrog AI shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Fortrea and Bullfrog AI, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortrea | 1 | 5 | 5 | 0 | 2.36 |
| Bullfrog AI | 1 | 1 | 0 | 0 | 1.50 |
Fortrea currently has a consensus price target of $22.00, suggesting a potential upside of 10.61%. Given Fortrea’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Fortrea is more favorable than Bullfrog AI.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
